Vistagen Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VTGN Nasdaq 2830 www.vistagen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vistagen Therapeutics, Inc.

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Jul 15th, 2026 3:22 am
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Jun 30th, 2026 6:00 am
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Jun 15th, 2026 2:30 pm
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder - Jun 9th, 2026 6:30 am
HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates - May 28th, 2026 3:40 pm
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates - May 20th, 2026 6:15 am
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - May 19th, 2026 5:08 am
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates - May 18th, 2026 7:00 am
VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary - Feb 13th, 2026 6:30 am
Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ... - Feb 12th, 2026 10:02 pm
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates - Feb 12th, 2026 3:45 pm
US Equity Markets Fall as Technology Stocks Slump Amid Oracle Concerns - Dec 17th, 2025 2:22 pm
Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... - Nov 13th, 2025 10:06 pm
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates - Nov 13th, 2025 3:55 pm
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2025 6:45 am
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates - Nov 5th, 2025 3:45 pm
Vistagen Therapeutics (VTGN): Examining Valuation After Phase 3 Trial Progress Toward Social Anxiety Treatment Approval - Nov 4th, 2025 7:19 am
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Nov 2nd, 2025 3:05 am
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - Oct 30th, 2025 6:15 am
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates - Oct 29th, 2025 3:20 pm